What's Happening?
Natera has announced the completion of enrollment in the ACES-EMB trial, a randomized-controlled study evaluating the use of its Prospera Heart test for non-invasive rejection monitoring in heart transplant recipients. The trial aims to compare the effectiveness
of donor-derived cell-free DNA (dd-cfDNA) surveillance with traditional biopsy methods. Over 300 patients across 17 U.S. transplant centers have been enrolled, and the study will assess whether the Prospera test can replace routine biopsies, potentially transforming post-transplant care.
Why It's Important?
The ACES-EMB trial represents a significant step towards improving the standard of care for heart transplant patients. If successful, the Prospera Heart test could reduce the need for invasive biopsies, which are costly and carry risks of complications. This advancement would enhance patient safety and comfort while providing reliable monitoring for organ rejection. The trial's outcomes could influence clinical practices and guidelines, promoting wider adoption of non-invasive diagnostic tools in transplant medicine.
